Agreement Between Physician Evaluation and the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis
- Resource Type
- Authors
- Zheng, B.Y.; Wang, M.B.; McKenna, K.; Shapiro, L.; Silver, R.; Csuka, M.E.; Hoogen, F. van den; Robinson, D.; Pauling, J.D.; Hummers, L.; Krieg, T.; Galdo, F. del; Spiera, R.; Jones, N.; Khalidi, N.; Vacca, A.; Vries-Bouwstra, J.K. de; Gordon, J.; Baron, M.; Canadian Scleroderma Res Grp
- Source
- Arthritis Care & Research, 74(11), 1806-1812. WILEY
- Subject
- Index (economics)
Rheumatology
business.industry
Medicine
Nuclear medicine
business
- Language
- English
Objective Diffuse cutaneous systemic sclerosis (SSc) is a highly heterogeneous disease. A provisionally approved Composite Response Index in diffuse cutaneous SSc (CRISS) was developed as a 1-year outcome measure for clinical trials. Our goal was to further validate the CRISS by examining agreement between CRISS definitions for improved/non-improved with physicians' evaluation of disease. Methods Patient profiles from a large observational cohort were created for 50 random diffuse cutaneous SSc patients of